BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 27080811)

  • 1. Increased prevalence of prior malignancies and autoimmune diseases in patients diagnosed with chronic myeloid leukemia.
    Gunnarsson N; Höglund M; Stenke L; Wållberg-Jonsson S; Sandin F; Björkholm M; Dreimane A; Lambe M; Markevärn B; Olsson-Strömberg U; Wadenvik H; Richter J; Själander A
    Leukemia; 2016 Jul; 30(7):1562-7. PubMed ID: 27080811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era.
    Gunnarsson N; Stenke L; Höglund M; Sandin F; Björkholm M; Dreimane A; Lambe M; Markevärn B; Olsson-Strömberg U; Richter J; Wadenvik H; Wallvik J; Själander A
    Br J Haematol; 2015 Jun; 169(5):683-8. PubMed ID: 25817799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of Second Malignancies of Chronic Myeloid Leukemia During Treatment With Tyrosine Kinase Inhibitors.
    Yin XF; Wang JH; Li X; Yu MX; Ma ZX; Jin J
    Clin Lymphoma Myeloma Leuk; 2016 Oct; 16(10):577-581. PubMed ID: 27397576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are chronic myeloid leukemia patients more at risk for second malignancies? A population-based study.
    Rebora P; Czene K; Antolini L; Gambacorti Passerini C; Reilly M; Valsecchi MG
    Am J Epidemiol; 2010 Nov; 172(9):1028-33. PubMed ID: 20861143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population-based assessment of chronic myeloid leukemia in Sweden: striking increase in survival and prevalence.
    Gunnarsson N; Sandin F; Höglund M; Stenke L; Björkholm M; Lambe M; Olsson-Strömberg U; Richter J; Själander A
    Eur J Haematol; 2016 Oct; 97(4):387-92. PubMed ID: 26833713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Childbearing and the risk of leukemia in Sweden.
    Ekström K; Wuu J; Hsieh CC; Glimelius B; Lambe M
    Cancer Causes Control; 2002 Feb; 13(1):47-53. PubMed ID: 11899117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-treatment-related chronic myeloid leukemia as a second malignancy.
    Specchia G; Buquicchio C; Albano F; Liso A; Pannunzio A; Mestice A; Rizzi R; Pastore D; Liso V
    Leuk Res; 2004 Feb; 28(2):115-9. PubMed ID: 14654074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of second malignancies during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors in the Czech Republic and Slovakia.
    Voglova J; Muzik J; Faber E; Zackova D; Klamova H; Steinerova K; Michalovicova Z; Demitrovicova L; Cmunt E; Novakova L; Tothova E; Belohlavkova P; Mayer J; Indrak K
    Neoplasma; 2011; 58(3):256-62. PubMed ID: 21395367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
    Sasaki K; Kantarjian HM; O'Brien S; Ravandi F; Konopleva M; Borthakur G; Garcia-Manero G; Wierda WG; Daver N; Ferrajoli A; Takahashi K; Jain P; Rios MB; Pierce SA; Jabbour EJ; Cortes JE
    Int J Hematol; 2019 May; 109(5):545-552. PubMed ID: 30830579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk and survival of chronic myeloid leukemia after breast cancer: A population-based study.
    Al-Husseini MJ; Mohamed HH; Saad AM; Gad MM; Atia M; Qaddoora U; Abushouk AI; El-Shinawi M
    Curr Probl Cancer; 2019 Jun; 43(3):213-221. PubMed ID: 30195804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using healthcare claims data to analyze the prevalence of BCR-ABL-positive chronic myeloid leukemia in France: A nationwide population-based study.
    Foulon S; Cony-Makhoul P; Guerci-Bresler A; Delord M; Solary E; Monnereau A; Bonastre J; Tubert-Bitter P
    Cancer Med; 2019 Jun; 8(6):3296-3304. PubMed ID: 31038849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of comorbid disease history on all-cause and cancer-specific mortality in myeloid leukemia and myeloma - a Swedish population-based study.
    Mohammadi M; Cao Y; Glimelius I; Bottai M; Eloranta S; Smedby KE
    BMC Cancer; 2015 Nov; 15():850. PubMed ID: 26537111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic myeloid leukemia incidence, survival and accessibility of tyrosine kinase inhibitors: a report from population-based Lithuanian haematological disease registry 2000-2013.
    Beinortas T; Tavorienė I; Žvirblis T; Gerbutavičius R; Jurgutis M; Griškevičius L
    BMC Cancer; 2016 Mar; 16():198. PubMed ID: 26956037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy-related chronic myeloid leukemia: an epidemiological, clinical and pathogenetic appraisal.
    Aguiar RC
    Leuk Lymphoma; 1998 Mar; 29(1-2):17-26. PubMed ID: 9638972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of chronic myeloid leukemia and patient survival: results of five French population-based cancer registries 1980-2009.
    Penot A; Preux PM; Le Guyader S; Collignon A; Herry A; Dufour V; Monnereau A; Woronoff AS; Troussard X; Pons E; Bordessoule D; Maynadié M
    Leuk Lymphoma; 2015 Jun; 56(6):1771-7. PubMed ID: 25535815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV.
    Miranda MB; Lauseker M; Kraus MP; Proetel U; Hanfstein B; Fabarius A; Baerlocher GM; Heim D; Hossfeld DK; Kolb HJ; Krause SW; Nerl C; Brümmendorf TH; Verbeek W; Fauser AA; Prümmer O; Neben K; Hess U; Mahlberg R; Plöger C; Flasshove M; Rendenbach B; Hofmann WK; Müller MC; Pfirrmann M; Hochhaus A; Hasford J; Hehlmann R; Saußele S
    Leukemia; 2016 Jun; 30(6):1255-62. PubMed ID: 26859076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Descriptive epidemiology of myeloid leukemia].
    Matsuo K; Ito H
    Nihon Rinsho; 2009 Oct; 67(10):1847-51. PubMed ID: 19860178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic myeloid leukemia in a patient with colon adenocarcinoma.
    Gokel Y; Paydas S
    Haematologia (Budap); 2002; 32(4):501-3. PubMed ID: 12803125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Community-acquired infections and their association with myeloid malignancies.
    Titmarsh GJ; McMullin MF; McShane CM; Clarke M; Engels EA; Anderson LA
    Cancer Epidemiol; 2014 Feb; 38(1):56-61. PubMed ID: 24275260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.